WO2006014726A3 - Immunoglobulines comprenant principalement une glycoforme man5glcnac2 - Google Patents

Immunoglobulines comprenant principalement une glycoforme man5glcnac2 Download PDF

Info

Publication number
WO2006014726A3
WO2006014726A3 PCT/US2005/025731 US2005025731W WO2006014726A3 WO 2006014726 A3 WO2006014726 A3 WO 2006014726A3 US 2005025731 W US2005025731 W US 2005025731W WO 2006014726 A3 WO2006014726 A3 WO 2006014726A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycoform
immunoglobulins
predominantly
relates
present
Prior art date
Application number
PCT/US2005/025731
Other languages
English (en)
Other versions
WO2006014726A2 (fr
Inventor
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Original Assignee
Glycofi Inc
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycofi Inc, Tillman U Gerngross, Huijuan Li, Stefan Wildt filed Critical Glycofi Inc
Priority to AU2005269713A priority Critical patent/AU2005269713A1/en
Priority to CA002573554A priority patent/CA2573554A1/fr
Priority to JP2007522696A priority patent/JP2008507535A/ja
Priority to EP05790364A priority patent/EP1771478A2/fr
Publication of WO2006014726A2 publication Critical patent/WO2006014726A2/fr
Publication of WO2006014726A3 publication Critical patent/WO2006014726A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions de glycoprotéines d'immunoglobulines présentant des structures à N-glycane prédominant situées sur une glycoprotéine d'immunoglobuline, ce qui confère une fonction d'effecteur spécifique à ces compositions. En outre, l'invention concerne des compositions pharmaceutiques comprenant un anticorps présentant une structure particulière enrichie en N-glycane, ladite structure étant de formule Man5GlcNAc2.
PCT/US2005/025731 2004-07-21 2005-07-19 Immunoglobulines comprenant principalement une glycoforme man5glcnac2 WO2006014726A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2005269713A AU2005269713A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a Man5GlcNac2 glycoform
CA002573554A CA2573554A1 (fr) 2004-07-21 2005-07-19 Immunoglobulines comprenant principalement une glycoforme man<sb>5</sb>glcnac<sb>2</sb>
JP2007522696A JP2008507535A (ja) 2004-07-21 2005-07-19 主にｍａｎ５ｇｌｃｎａｃ２グリコフォームを含むイムノグロブリン
EP05790364A EP1771478A2 (fr) 2004-07-21 2005-07-19 Immunoglobulines comprenant principalement une glycoforme man5glcnac2

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58997904P 2004-07-21 2004-07-21
US58992604P 2004-07-21 2004-07-21
US60/589,979 2004-07-21
US60/589,926 2004-07-21

Publications (2)

Publication Number Publication Date
WO2006014726A2 WO2006014726A2 (fr) 2006-02-09
WO2006014726A3 true WO2006014726A3 (fr) 2006-07-20

Family

ID=35506030

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025731 WO2006014726A2 (fr) 2004-07-21 2005-07-19 Immunoglobulines comprenant principalement une glycoforme man5glcnac2

Country Status (5)

Country Link
EP (1) EP1771478A2 (fr)
JP (1) JP2008507535A (fr)
AU (1) AU2005269713A1 (fr)
CA (1) CA2573554A1 (fr)
WO (1) WO2006014726A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063776A2 (fr) 2006-10-12 2008-05-29 Genentech, Inc. Anticorps de la lymphotoxine-alpha
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1211310A1 (fr) * 1999-08-19 2002-06-05 Kirin Beer Kabushiki Kaisha Nouvelles variantes de levure et procede de production de glycoproteine
WO2004074499A2 (fr) * 2003-02-20 2004-09-02 Gerngross Tillman U Banques adn combinatoires destinees a produire des n-glycanes modifies dans des eucaryotes inferieurs
EP1505149A1 (fr) * 2002-04-26 2005-02-09 Kirin Beer Kabushiki Kaisha Methylotrophe produisant une chaine de sucre de type mammifere

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1211310A1 (fr) * 1999-08-19 2002-06-05 Kirin Beer Kabushiki Kaisha Nouvelles variantes de levure et procede de production de glycoproteine
EP1505149A1 (fr) * 2002-04-26 2005-02-09 Kirin Beer Kabushiki Kaisha Methylotrophe produisant une chaine de sucre de type mammifere
WO2004074499A2 (fr) * 2003-02-20 2004-09-02 Gerngross Tillman U Banques adn combinatoires destinees a produire des n-glycanes modifies dans des eucaryotes inferieurs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIBA YASUNORI ET AL: "Production of human compatible high mannose-type (Man5GlcNAc2) sugar chains in Saccharomyces cerevisiae", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 273, no. 41, 9 October 1998 (1998-10-09), pages 26298 - 26304, XP002202331, ISSN: 0021-9258 *
CHOI B-K ET AL: "Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 9, 29 April 2003 (2003-04-29), pages 5022 - 5027, XP002267831, ISSN: 0027-8424 *
SHINKAWA T ET AL: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 5, 31 January 2003 (2003-01-31), pages 3466 - 3473, XP002965857, ISSN: 0021-9258 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8883483B2 (en) 2000-06-28 2014-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Also Published As

Publication number Publication date
JP2008507535A (ja) 2008-03-13
EP1771478A2 (fr) 2007-04-11
CA2573554A1 (fr) 2006-02-09
WO2006014726A2 (fr) 2006-02-09
AU2005269713A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2006071856A3 (fr) Immunoglobulines comprenant principalement une glycoforme man5glcnac2
WO2006014683A3 (fr) Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2
WO2006066568A3 (fr) Anticorps
WO2007147122A3 (fr) Anticorps monoclonaux qui reconnaissent sélectivement des composés de méthamphétamine et de type méthamphétamine
WO2008091798A3 (fr) Anticorps de ca9 optimises et methodes d&#39;utilisation associees
WO2006094192A3 (fr) Anticorps humanises l243
WO2007129895A3 (fr) Anticorps monoclonal antagoniste anti-cd40 humain
WO2006104989A3 (fr) Anticorps a regions fc modifiees et utilisations
WO2006020114A3 (fr) Regions fc de variants
WO2007050569A3 (fr) Films de polypeptide multicouches et procedes
WO2003102066A3 (fr) Dispersions aqueuses d&#39;adhesif
MY150621A (en) Anti-epha2 antibody
WO2002075274A3 (fr) Methode et trousse pour le suivi des maladies neurodegeneratives
WO2006119056A3 (fr) Vehicule supersonique plus leger que l&#39;air
WO2007063415A3 (fr) Procedes de production de lymphocytes b stables
WO2005067848A3 (fr) Procede de collage de surfaces sur une bande
WO2006014726A3 (fr) Immunoglobulines comprenant principalement une glycoforme man5glcnac2
EP1344827A3 (fr) Protéines antigel de basidiomycètes
WO2005035490A3 (fr) Procede de synthese de d-tocotrienols
WO2004075021A3 (fr) Procedes de modelisation moleculaire
FR2855557B1 (fr) Volet de tuyere a duree de vie augmentee pour turbomoteurs d&#39;avion.
NL1021490A1 (nl) Werkwijze voor de bereiding van een fluorpolymeer.
WO2007036501A3 (fr) Copolymere greffe et son utilisation
WO2005057042A3 (fr) Materiau de friction
ITTO20021050A1 (it) Struttura di carenatura di un veicolo.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2573554

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005790364

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007522696

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005269713

Country of ref document: AU

Ref document number: 200580024712.6

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1209/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005269713

Country of ref document: AU

Date of ref document: 20050719

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005269713

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005790364

Country of ref document: EP